Navigation Links
Creabilis Appoints Professor Gil Yosipovitch and Professor Praveen Anand to its Scientific Advisory Board
Date:7/29/2013

has the potential to make a real difference to the lives of patients suffering from the condition. I look forward to working with the experienced Creabilis team to help achieve this goal."

Professor Praveen Anand, commenting on his appointment, said: "I'm delighted to join the Creabilis Scientific Board. Neuropathic pain is an area of significant unmet need. CT340, with its novel dual analgesic and anti-inflammatory mechanism of action and strong pre-clinical data has the potential to meet this need. Creabilis is at an exciting stage of its development, with CT327 in late stage development for chronic pruritus and CT340 IND-ready in neuropathic pain. Given the mechanistic similarities between pruritus and pain, I am excited to begin working with Creabilis to realise the potential of both CT340 and CT327."

Professor Jonathan Barker, Chair of the Scientific Advisory Board said: "Professors Anand and Yosipovitch bring further world-class expertise to an outstanding Advisory Board which will allow the Board to provide key scientific and clinical advice to Creabilis. It is a reflection of the quality of Creabilis' recent clinical data with CT327 in chronic pruritus, and pre-clinical data with CT340 in neuropathic pain, that we have been able to attract individuals of Gil and Praveen's calibre to our Scientific Advisory Board."  

About Creabilis SA

Creabilis is a late clinical stage European biotechnology company with a primary focus in chronic pruritus (itch), a debilitating symptom of many dermatological diseases with a negative impact on quality of life. Chronic pruritus is an area of significant unmet need, with no medicine currently approved for its treatment.

Creabilis has delivered positive Phase 2b results for CT327 in the treatment of pruritus in psoriasis patients. CT327 is a novel, first-in-class, topically delivered TrkA kinase inhibitor. CT327 was developed using
'/>"/>

SOURCE Creabilis SA
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related biology technology :

1. Creabilis Appoints Catherine Moukheibir to its Board of Directors
2. Creabilis Receives Prestigious Technology Strategy Board Biomedical Catalyst Award
3. Alexander Proudfoot Appoints Executive Vice President for Life Sciences
4. KemPharm, Inc. Appoints Gordon K. "Rusty" Johnson as Chief Operating Officer and Chief Financial Officer
5. KaloBios Appoints Donald R. Joseph as Chief Legal Officer
6. Organovo Appoints Tamar D. Howson to Board of Directors
7. Microvi Biotechnologies Appoints Former COO of Zenon Environmental as Chairman of Board of Directors
8. PTC Therapeutics Appoints Shane Kovacs as Chief Financial Officer
9. SPIE Appoints Ni-Bin Chang Editor of Journal of Applied Remote Sensing
10. Envera Appoints Michael McErlean Fermentation Manager
11. WMIS Appoints Lisa Baird as Next Executive Director
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/19/2014)... (PRWEB) August 19, 2014 In November 2012, ... Benefit Risk Evaluation Report (PBRER) in a new PSUR – ... post-authorization safety benefit-risk profile of a drug. Adopted in many ... , Present a comprehensive and critical analysis of ... , Highlight any new evidence of the potential ...
(Date:8/19/2014)... /PRNewswire/ - iCo Therapeutics Inc. ("iCo" or "the Company") ... its Oral Amphotericin B (Oral Amp B) drug ... by ImmuneCarta®, the immune monitoring business unit of ... Oral Amp B in reactivating latent HIV viral ... treatment with antiretroviral therapy. Memory ...
(Date:8/18/2014)... 2014 Deep Research Report on ... and in-depth research report on the China Linalool ... including its definition, classification, application, and industry chain ... covers the international market analysis, including China’s domestic ... macroeconomic environment & economic situation analysis. The report ...
(Date:8/18/2014)... Diagnostics Inc. (TSX-V: SQD), a life sciences company that ... microarray diagnostics, today announced it will hold an investor ... ET.  During the call, Andrew ... SQI,s recent commercialization progress and then introduce Dr. ... to the Board of Directors of SQI and also ...
Breaking Biology Technology:Top Five Best Practices for Developing Your Periodic Benefit Risk Evaluation Report (PBRER), New Webinar Hosted by Xtalks 2iCo Therapeutics Announces Positive Oral Amphotericin B Study Results 2iCo Therapeutics Announces Positive Oral Amphotericin B Study Results 3Linalool Industry & Diphenylamine Market (Global, China) 2014 Analysis Now Available at DeepResearchReports.com 2Linalool Industry & Diphenylamine Market (Global, China) 2014 Analysis Now Available at DeepResearchReports.com 3Linalool Industry & Diphenylamine Market (Global, China) 2014 Analysis Now Available at DeepResearchReports.com 4SQI Diagnostics Announces Investor Conference Call with Dr. Allan Pronovost 2SQI Diagnostics Announces Investor Conference Call with Dr. Allan Pronovost 3
... Crystal Research Associates, LLC announced today that it ... Inc. (NYSE Amex: CUR ). The full ... .Neuralstem, Inc. ("Neuralstem" or "the Company") is a ... stem cells to treat central nervous system (CNS) diseases. ...
... /PRNewswire-Asia/ -- Pharmaxis Ltd (AXS: PXS;,Nasdaq: PXSL ) ... afternoon of Wednesday 8th April 2009. Dr Alan Robertson ... quarter and answer,investor questions. , The ... 8th April at 6.00pm U.S. East Coast, 3.00pm U.S. West ...
... April 6 Cell Therapeutics, Inc. (CTI) (Nasdaq and ... from Spectrum Pharmaceuticals, Inc. (Spectrum) in connection with the ... venture to Spectrum for approximately $16.5 million that closed ... on March 2, 2009, related to this transaction, and ...
Cached Biology Technology:Crystal Research Associates, LLC Issues Executive Informational Overview(R) (EIO(R)) on Neuralstem, Inc. 2Crystal Research Associates, LLC Issues Executive Informational Overview(R) (EIO(R)) on Neuralstem, Inc. 3CTI Receives the Second Payment of $6.5 million Associated with the Sale of Interest in Zevalin Joint Venture 2CTI Receives the Second Payment of $6.5 million Associated with the Sale of Interest in Zevalin Joint Venture 3
(Date:8/20/2014)... and POINT ROBERTS, Washington , ... Play a Key Role in Addressing Security Concerns in the ... a global news source covering leading sectors including biometrics, issues ... market. Jason Peaslee , Managing Partner at ... and Gino Pereira , CEO of NXT-ID, Inc. (OTCBB: ...
(Date:8/19/2014)... used in supermarkets to encourage healthier spending habits? A ... that very question by tracking the purchasing records in ... to rate the nutritional value of foods for sale. ... David Just, PhD, and Brian Wansink PhD, author of ... over 150 Hannaford Supermarkets in the Northeastern United States ...
(Date:8/19/2014)... In many parts of the world, leprosy and ... new cases of leprosy per year, with nearly ... The currently available century-old vaccine Bacille Calmette-Guerin, or ... and leprosy, so a more potent vaccine is ... have found a stronger weapon against both diseases., ...
Breaking Biology News(10 mins):Digital Wallets for a Digital World - the Players and the Concerns for Consumer Adoption 2Digital Wallets for a Digital World - the Players and the Concerns for Consumer Adoption 3Digital Wallets for a Digital World - the Players and the Concerns for Consumer Adoption 4Digital Wallets for a Digital World - the Players and the Concerns for Consumer Adoption 5Digital Wallets for a Digital World - the Players and the Concerns for Consumer Adoption 6Digital Wallets for a Digital World - the Players and the Concerns for Consumer Adoption 7New vaccine shows promise as stronger weapon against both tuberculosis and leprosy 2
... French . , Quebec City, August 25, 2011A diet rich ... according to a study conducted by Universit Laval researchers. The team, ... extent of brain damage following a stroke was reduced by 25% ... study can be found on the website of the journal ...
... DURHAM, N.C. Aerobic exercise is your best bet when ... study finds. When Duke University Medical Center researchers conducted ... combination of the two, they found aerobic exercise to be ... belly fat that,s most damaging to your health. This ...
... have developed the first practical method to create a compound ... naturally in a species of moss found in China, is ... disease in China since the late 1990s and is sold ... memory. Scientists believe it could also potentially combat the effects ...
Cached Biology News:Omega-3s reduce stroke severity 2Aerobic exercise bests resistance training at burning belly fat 2Scientists create natural Alzheimer's-fighting compound in lab 2
... Isolated Sequence) siRNA Test System is designed ... of a potential of any DNA sequence ... RNA interference (RNAi). Current computer-based RNAi target ... probability of selected sequence to be a ...
... Stabilizer is a is a bovine protein-free ... product is an aqueous solution that contains ... buffered saline), pH 6.6 - 7.2. ... methylisothiazolone and 0.02% bromonitrodioxane as a preservative. ...
... Mouse anti-Yersinia pestis F1 antigen, Monoclonal ... ELISA: Use at an ... an assay dependent dilution. WB: Use ... molecular weight: 18 kDa. Not tested ...
... This mounting medium is specifically formulated for ... which have been stained with immunohistochemical methods ... ideal for use with chromogens, such as ... organic solvents. Faramount dries completely when slides ...
Biology Products: